Overview

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the distribution of IARs by severity grade when LEMTRADA is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion associated reactions.
Phase:
Phase 4
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Acetaminophen
Acyclovir
Alemtuzumab
Cetirizine
Esomeprazole
Ibuprofen
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Ranitidine